OZEM vs PBPH

OZEMCRoundhill GLP-1 & Weight Loss ETF

PBPHBPortfolio Building Block World Pharma and Biotech Index ETF

In short

OZEM The whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.

PBPH Most biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

Stated mandate

OZEM The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.

PBPH The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

Why people hold it

• OZEM The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
• A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
• At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.

• PBPH 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
• Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
• Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
• Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

Worth knowing

• OZEM Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
• Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
• Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.

• PBPH One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
• Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
• Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

Full OZEM profile⁠

Full PBPH profile⁠